01011 NT PHARMA
- 0.024
- -0.001-4.00%
NT PHARMA News
Improve quality and expand! The National Health Insurance Administration issued a new collection document “There is a lot of information” to set the tone for new trends in collection and procurement
① Yesterday evening, the National Health Insurance Administration issued the “Notice on Strengthening Regional Collaboration to Improve Quality and Expand Centralized Pharmaceutical Procurement in 2024", which provides further instructions on “improving quality and expansion” of collection; ② Many interprovincial alliance procurement will soon be upgraded to national joint procurement, which has attracted strong attention from the industry. In particular, the provinces covered by the Sanming Alliance and Henan Alternative Medicine Alliance will be further expanded, and proprietary Chinese medicine and Chinese medicine tablet companies need to prepare early.
A record high! The total number of clinical trials exceeded 4,000 in 2023
According to the report, in 2023, the total number of clinical trials registered on the drug clinical trial registration and information disclosure platform surpassed 4,000 for the first time, reaching 4,300 (in terms of CTR), the highest total number of registrations in history, an increase of 26.1% over the total number of registrations in 2022.
NT PHARMA To Carry Out 1-for-10 Reverse Stock Split On July 3rd, 2024
May 15th - $NT PHARMA(01011.HK)$ is about to implement a 1-for-10 reverse stock split of shares. The shares will begin trading on a split-adjusted basis from July 3rd, 2024.$NT PHARMA(01011.HK)$ rose
Tailing Pharmaceuticals (01011.HK) proposes to change the trading unit for each lot of “10 in 1” shares to 10,000 shares
Gelonghui, May 14, 丨 Tailing Pharmaceutical (01011.HK) announced that the board of directors proposed a “10 in 1” share merger. Stock consolidation is subject to shareholders' approval at a special shareholders' meeting before it can actually take place. After the share merger comes into effect, it is proposed to change the trading unit for each lot traded on the Stock Exchange from 500 existing shares to 10,000 consolidated shares.
Tailing Pharmaceutical (01011) plans to implement a share merger based on a “10 in 1” basis
Zhitong Finance App News, Tailing Pharmaceutical (01011) announced that the board of directors proposed a share consolidation based on the basis of merging issued and unissued shares with a face value of 0.00000008 US dollars per 10 shares into 1 consolidated share of 0.0000008 US dollars per share. On the date of this announcement, existing shares were traded on the Stock Exchange with 500 existing shares per lot. After the share merger comes into effect, it is proposed to change the trading unit for each lot traded on the Stock Exchange from 500 existing shares to 10,000 consolidated shares.
Express News | Galaxy Securities: Judging from the pace of the industry's revenue growth rate, the first quarter of 2024 is expected to be the lowest point in the pharmaceutical industry in the whole year
The medical news is huge! Will Pharmacokinetics usher in a turning point? US pharmaceutical company contract exemption or extension for 8 years
Industry insiders believe that 8 years is enough time for relevant companies to adapt, and the implementation of this greatest uncertainty can also have a positive impact on related companies.
Express News | Guotai Junan: Pharmaceutical industry prosperity is expected to continue to improve
泰凌醫藥：2023 年報
Express News | National Health Insurance Administration: Nine batches of state-organized drugs collected domestically produced generic drugs, accounting for 96%
Accelerating the integration of obstetrics and medicine! How to deal with the “two ends” problem during the differentiation period of pharmaceutical innovation? Industry figures predict future internal volume reduction
① The 7th Pharmaceutical Innovation Ecology Conference (2024 Xipai Conference) with the theme of “Reconstructing R&D and Clinical Value Transformation Ecology through the Differentiation Period” opened in Zhangjiang, Shanghai. ② How to achieve original innovation with high quality and high value, and how to efficiently commercialize post-marketing products and achieve clinical value are the focus of this conference. ③ Many participants made a judgment that domestic pharmaceutical companies will reduce internal volume in the future.
Innovative drugs continue to warm up! Joint policies in many places catalyze the strengthening of the pharmaceutical sector in Hong Kong stocks
Recently, support policies for the innovative pharmaceutical industry have been issued in many places, bringing a new market catalyst to the currently relatively deserted pharmaceutical stocks. The Hong Kong stock pharmaceutical sector is also active today.
Multiple arrows in unison! Pharmaceutical innovation support policies are coming
Recently, many places, including Beijing, Guangzhou, and Zhuhai, have successively issued relevant policies (draft for comments) to support the high-quality development of the biomedical industry or innovative pharmaceutical devices. The intensive introduction of support policies and the tight schedule have attracted great attention from the industry.
Tailing Pharmaceutical (01011) announced annual results. Shareholders' losses of 144 million yuan increased by 116.23% year-on-year
According to the Zhitong Finance App, Tailing Pharmaceutical (01011) announced the audited annual results for the year ended December 31, 2023. The group achieved continuous business revenue of 7.366 million yuan (RMB, same below) during the period, with no revenue in the same period of the previous year; shareholders should have accounted for a loss of 144 million yuan, an increase of 116.23% over the previous year; and a basic loss of 7.26 points per share. The announcement stated that the increase in revenue was due to a change in the business model in 2023.
泰凌醫藥：截至2023 年12 月31日止年度經審核全年業績公告
Hong Kong pharmaceutical stocks bucked the trend, and Pharmacovigilance led their sector. Is the “Biosafety Act” or a biological variable?
① Why is the market paying attention to the Biosafety Act? ② How has Yao Ming Kangde performed recently?
Tailing Pharmaceutical (01011.HK) plans to hold a board meeting on March 28 to consider and approve the annual results
Gelonghui, March 19, 丨 Tailing Pharmaceutical (01011.HK) announced that the company will hold a board meeting on March 28, 2024 (Thursday) to approve (among other things) the publication of the annual results of the company and its subsidiaries for the year ended December 31, 2023.
NT PHARMA: DATE OF BOARD MEETING
Yao Ming Kangde was removed from BIO membership! Where will the domestic innovative drug sector go?
The path to the rise of innovative drugs doesn't seem easy!
Not only is Daimo bullish, but Xiaoma has taken steps to increase its holdings of the drug Ming Kangde. Major international banks are turning one after another, and the Hong Kong stock pharmaceutical industry is welcoming a “crouching and leap”?
① Hong Kong stocks of Innovative Pharmaceuticals soared at the end of yesterday. Collumbotai Biotech B rose 14.9%; Rongchang Biotech rose 14.8%; Connoya B rose 12.8%; ② Although “Yao Mao” Pharmaceutical Kangde Hong Kong shares closed down 1.16%, the decline narrowed sharply at the end of the session, and J.P. Morgan increased its holdings by 1.654 million shares, or HK$77.68 million.
Analysis
Price Target
No Data
